INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, ...
In a meta-analysis published in Gut Microbes, investigators pooled shotgun metagenomic sequencing data to examine how gut ...
When most people think of concussion, the first type of patient that comes to mind is a youth athlete. However, concussion is ...
Allo-HSCT significantly improved survival in real-world pediatric AML, with CR1 patients showing the best outcomes, achieving OS and DFS rates of 84.2% and 73.4%. Matched sibling and unrelated donors ...
Larimar Therapeutics has initiated dosing for adolescents aged 12-17 in its pediatric pharmacokinetic (PK) run-in study for nomlabofusp, a potential treatment for Friedreich’s ataxia. Adolescents who ...
Bayer revealed first results of the pediatric study from the pivotal clinical development program QUANTI for its low-dose MRI contrast agent QUANTI Pediatric evaluated the pharmacokinetics and safety ...
Quoin Pharmaceuticals Ltd. announced positive interim results from its clinical study of QRX003 for treating Pediatric Netherton Syndrome, showing significant improvements in skin appearance. After ...
Despite missing the primary endpoint in a pediatric study, Agios says it remains steadfast in working to grow the reach of its pyruvate kinase (PK) activation franchise. Agios hopes to fill the ...
Fig 1 Thematic divergence and convergence. Venn diagram demonstrating thematic divergence and convergence among sites. Fig 2 Stigma model for pediatric cancer. Stigma model adapted from the Health ...
Emergency departments (EDs) that saw fewer kids were more likely to have potentially delayed diagnoses for serious acute conditions in that population, a large retrospective cohort study showed. For ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results